<DOC>
	<DOCNO>NCT02687477</DOCNO>
	<brief_summary>This project focus treatment severe obstructive sleep apnea pulmonary artery denervation ( PADN ) . Although proved continuous positive airway pressure ( CPAP ) primary treatment obstructive sleep apnea , hand , evidence 25 50 % patient tolerate CPAP . The investigator previously report safety efficacy pulmonary artery denervation ( PADN ) treatment pulmonary hypertension . Excessive sympathetic activation play important role occurrence development OSA cause cardiovascular event . It worth evaluate feasibility tolerance introduce PADN severe stage obstructive sleep apnea . Therefore , purpose study evaluate safety feasibility PADN treatment severe OSA .</brief_summary>
	<brief_title>PADN Treat Severe Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Apnea hypopnea index 30 , tolerate refuse continuous positive airway pressure ; Acute coronary syndrome ; Pregnant ; Expected life le 12 month ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>